Teeling M, Bennett K, Feely J
Department of Pharmacology and Therapeutics, Trinity College/St James's Hospital, Dublin, Ireland.
Br J Clin Pharmacol. 2005 Feb;59(2):227-32. doi: 10.1111/j.1365-2125.2004.02256.x.
To monitor statin prescribing trends over time in order to determine whether prescribers were influenced by study results and/or clinical guidelines in terms of type and dosage of statin prescribed.
The GMS (General Medical Services) prescription database in Ireland was used to identify a cohort of patients, prescribed statins, in order to investigate prescribing trends from January 1998-December 2002. Statin prescribing rates for patients with ischaemic heart disease and diabetes were compared with rates in the general GMS population. Logistic regression analysis was used in patients with ischaemic heart disease and diabetes and adjusted odds ratios and 95% confidence intervals presented.
Increased statin prescribing over time was noted (test for linear trend P < 0.0001). Pravastatin was the most frequently prescribed, followed by atorvastatin; simvastatin and fluvastatin showed lower rates of prescribing. Atorvastatin showed the greatest increased rate over time. An increase in the overall dose prescribed (test for trend P < 0.01) was chiefly due to increases in pravastatin dose, but doses were still below those recommended from clinical trials. Statins were prescribed more frequently in patients with ischaemic heart disease and diabetes, 44% (95% CI 43-45%) compared with the total GMS population, 7.7% (95% CI 7.6-7.8%), by December 2002. However, statins were only prescribed to 52% (95% CI 51-53%) of ischaemic heart disease patients and 40% (95% CI 39-41%) of patients with diabetes by December 2002. Patients aged 45-64 years were more likely to receive statins, compared with those aged 65 years and older.
These findings suggest that the beneficial effects of statins shown in clinical studies may not be achieved in practice.
监测他汀类药物随时间的处方趋势,以确定处方者在他汀类药物的类型和剂量方面是否受到研究结果和/或临床指南的影响。
利用爱尔兰的全科医疗服务(GMS)处方数据库确定一组服用他汀类药物的患者队列,以调查1998年1月至2002年12月的处方趋势。将缺血性心脏病和糖尿病患者的他汀类药物处方率与GMS总体人群的处方率进行比较。对缺血性心脏病和糖尿病患者进行逻辑回归分析,并给出调整后的优势比和95%置信区间。
注意到他汀类药物的处方量随时间增加(线性趋势检验P<0.0001)。普伐他汀是最常被处方的药物,其次是阿托伐他汀;辛伐他汀和氟伐他汀的处方率较低。阿托伐他汀随时间的增加率最高。总体处方剂量增加(趋势检验P<0.01)主要是由于普伐他汀剂量增加,但仍低于临床试验推荐的剂量。到2002年12月,缺血性心脏病和糖尿病患者中他汀类药物的处方频率更高,分别为44%(95%置信区间43-45%),而GMS总体人群为7.7%(95%置信区间7.6-7.8%)。然而,到2002年12月,只有52%(95%置信区间51-53%)的缺血性心脏病患者和40%(95%置信区间39-41%)的糖尿病患者服用了他汀类药物。与65岁及以上的患者相比,45-64岁的患者更有可能接受他汀类药物治疗。
这些发现表明,他汀类药物在临床研究中显示的有益效果在实际应用中可能无法实现。